Nivolumab blocks the interaction between PD-1 and PD-L1/PD-L2 to prevent the inhibitory signal from being transmitted, allowing T-cells to remain active and recognize and destroy tumor cells [19,29,30]. This evidence concerns the gene CD274 and neoplasm.